tiletamine hydrochloride has been researched along with Cancer of the Thyroid in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsuse, M; Meng, Z; Mitsutake, N; Nakashima, M; Namba, H; Ohtsuru, A; Saenko, V; Starenki, D; Takakura, S; Umezawa, K; Yamashita, S | 1 |
| Maeda, S; Namba, H; Ohtsuru, A; Saenko, VA; Starenki, DV; Umezawa, K; Yamashita, S | 1 |
| Namba, H; Saenko, V; Yamashita, S | 1 |
1 review(s) available for tiletamine hydrochloride and Cancer of the Thyroid
| Article | Year |
|---|---|
Nuclear factor-kB in thyroid carcinogenesis and progression: a novel therapeutic target for advanced thyroid cancer.
Topics: Animals; Apoptosis; Benzamides; Carcinoma; Cyclohexanones; Enzyme Activation; Humans; Inhibitor of Apoptosis Proteins; JNK Mitogen-Activated Protein Kinases; NF-kappa B; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Signal Transduction; Thyroid Neoplasms; Transcriptional Activation | 2007 |
2 other study(ies) available for tiletamine hydrochloride and Cancer of the Thyroid
| Article | Year |
|---|---|
Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Carcinoma; Cyclohexanones; Drug Synergism; Genes, p53; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; NF-kappa B; Peptides; Taxoids; Thyroid Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Topics: Apoptosis; Benzamides; Carcinoma; Cyclohexanones; Humans; NF-kappa B; Thyroid Neoplasms; Tumor Cells, Cultured | 2004 |